Glycosaminoglycans having an average molecular weight of 2400 D suitable for the treatment of senile dementia
US6979680B1 · kind B1 · utility
0Cited by
4References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 12, 2000 |
| Grant date | Dec 27, 2005 |
| Priority date | — |
| Expiry date | May 12, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC08B37/0078
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the use of glycosaminoglycans having an average/molecular weight of 2,400 D for the preparation of pharmaceutical compositions suitable for the treatment of senile dementia, in particular for the treatment of Alzheimer's disease or SDAT (Senile Dementia Alzheimer's Type) and of the cerebral neurological lesions from ictus and from traumas.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.